NCT06627712 - SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2029

Study Completion Date

November 1, 2031

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

SBRT+PD-1 Inhibitor + Chemotherapy

"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"

DRUG

PD-1 Inhibitor + Chemotherapy

"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"

All Listed Sponsors

lead

West China Hospital

OTHER